Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: A comparison of gadoxetic acid and gadobenate dimeglumine

Journal of Magnetic Resonance Imaging

Volumn 31, Issue 2, 2010, Pages 356-364

  Filippone, Antonella ^a   Blakeborough, Anthony ^b   Breuer, Josy ^c   Grazioli, Luigi ^d   Gschwend, Simone ^c   Hammerstingl, Renate ^e   Heinz Peer, Gertraud ^f   Kittner, Thomas ^g   Laghi, Andrea ^h   Leen, Edward ⁱ   Lencioni, Riccardo ^j   Lucidarme, Olivier ^k   Remplik, Philipp ^l   Robinson, Philip J ^m   Ruehm, Stefan G ⁿ   Schaefer, Fritz ^o   Stoupis, Christoforos ^p   Tombach, Bernd ^q,r   Valette, Pierre Jean ^s   Zech, Christoph J ^t   Huppertz, Alexander ^u   more..

^a UNIVERSITY OF CHIETI   (Italy)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c BAYER PHARMA AG   (Germany)

^d UNIVERSITY OF BRESCIA   (Italy)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f UNIV KLIN FÜR RADIODIAGNOSTIK   (Austria)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ GLASGOW ROYAL INFIRMARY   (United Kingdom)

^j UNIVERSITY OF PISA   (Italy)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l KLINIKUM AUGSBURG   (Germany)

^m ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^p UNIVERSITY OF BERN   (Switzerland)

^q UNIVERSITY OF MÜNSTER   (Germany)

^r Andreas Bannowsky Ltd   (Germany)

^s EDOUARD HERRIOT HOSPITAL   (France)

^t UNIVERSITY OF MUNICH   (Germany)

^u CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Contrast media; Gadolinium; Hepatocyte specific magnetic resonance (MR); Imaging; Liver cirrhosis

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOXETIC ACID;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SPECIFICITY; FATTY LIVER; FEMALE; HEMOCHROMATOSIS; HEMOSIDEROSIS; HEPATOGRAPHY; HUMAN; LIVER CELL; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; DOUBLE-BLIND METHOD; EUROPE; GADOLINIUM DTPA; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 75749105062     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22054     Document Type: Article

References (28)

1. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr 2006;30:345-354.
2. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-speci.c contrast agent: U.S. multicenter phase III study. Radiology 2005;237:89-98.
3. Hammerstingl R. Diagnostic efficacy of gadoxetic acid (Primovist® )-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008;18:457-467.
4. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004;230:266-275.
5. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging -a multicenter phase III clinical study. Radiology 2000;215: 727-736.
6. Balci NC, Semelka RC. Contrast agents for MR imaging of the liver. Radiol Clin North Am 2005;43:887-898,viii.
7. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology 2001;218:27-38.
8. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting poly-peptide Oatp1. J Pharmacol Exp Ther 1999;290:153-157.
9. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995;195: 785-792.
10. Schuhmann-Giampieri G, Mahler M, Roll G, Maibauer R, Schmitz S. Pharmacokinetics of the liver-specific contrast agent Gd-EOBDTPA in relation to contrast-enhanced liver imaging in humans. J Clin Pharmacol 1997;37:587-596.
11. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 1998;8: 862-867.
12. Rohrer M, Bauer H, Mintorovitch J, Requardt M, Weinmann HJ. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40: 715-724.
13. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996;199:177-183.
14. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers. Acad Radiol 1999;6:282-291.
15. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan. J Comput Assist Tomogr 1999; 23(Suppl 1):S65-S74.
16. Kaufman L, Kramer DM, Crooks LE, Ortendahl DA. Measuring signal-to-noise ratios in MR imaging. Radiology 1989;173: 265-267.
17. Del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations. Radiology 2002;225:766-772.
18. Schima W, Petersein J, Hahn PF, Harisinghani M, Halpern E, Saini S. Contrast-enhanced MR imaging of the liver: comparison between Gd-BOPTA and Mangafodipir. J Magn Reson Imaging 1997;7:130-135.
19. Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci 2005; 4:1-9.
20. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5(Suppl 1):S86-S89; discussion S93-S84.
21. Runge VM, Kenney CM. Phase II double-blind, dose-ranging clinical evaluation of gadobenate dimeglumine in focal liver lesions: with analysis of liver and kidney signal change on early and delayed imaging. J Magn Reson Imaging 2000;11:655-664.
22. Abdullah SS, Pialat JB, Wiart M, et al. Characterization of hepatocellular carcinoma and colorectal liver metastasis by means of perfusion MRI. J Magn Reson Imaging 2008;2:390-395.
23. van den Bos IC, Hussain SM, Dwarkasing RS, et al. MR imaging of hepatocellular carcinoma: relationship between lesion size and imaging findings, including signal intensity and dynamic enhancement patterns. J Magn Reson Imaging 2007;26: 1548-1555.
24. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67.
25. Marti-Bonmati L, Fog AF, de Beeck BO, Kane P, Fagertun H. Safety and efficacy of Mangafodipir trisodium in patients with liver lesions and cirrhosis. Eur Radiol 2003;13:1685-1692.
26. Marti-Bonmati L, Lonjedo E, Poyatos C, Casillas C. MnDPDP enhancement characteristics and differentiation between cirrhotic and noncirrhotic livers. Invest Radiol 1998;33:717-722.
27. Planchamp C, Montet X, Frossard JL, et al. Magnetic resonance imaging with hepatospecific contrast agents in cirrhotic rat livers. Invest Radiol 2005;40:187-194.
28. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004;14:559-578.